Results 141 to 150 of about 119,989 (312)

A good start of immunotherapy in esophageal cancer

Cancer Medicine, 2019
Considering the benefits of immunotherapy in advanced melanoma, non–small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is ...
Qian Zhao, Jinming Yu, Xue Meng
doaj   +1 more source

Recent Advances in mRNA Delivery Systems for Cancer Therapy

Advanced Science, EarlyView.
This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang, Ya‐Nan Fan, Si‐Qi Jiang, Ya‐Jing Ma, Yao‐Ru Yu, Yu‐Xin Qing, Qian‐Ru Li, Yi‐Lin Liu, Song Shen, Jun Wang   +9 more
wiley   +1 more source

Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors. [PDF]

, 2019
In 2017, the US Food and Drug Administration approved the first two novel cellular immunotherapies using synthetic, engineered receptors known as chimeric antigen receptors (CARs), tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta ...
Baybutt, Trevor R., Caparosa, Ellen M., Flickinger, John C., Snook, Adam E.   +3 more
core   +1 more source

Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies [PDF]

Immunotherapy is an effective precision medicine treatment for several cancers. Imaging signatures of the underlying genome (radiogenomics) in glioblastoma patients may serve as preoperative biomarkers of the tumor-host immune apparatus. Validated biomarkers would have the potential to stratify patients during immunotherapy clinical trials, and if ...
arxiv   +1 more source

Immunotyping the Tumor Microenvironment Reveals Molecular Heterogeneity for Personalized Immunotherapy in Cancer

Advanced Science, EarlyView.
This study develops TMEclassifier, a machine‐learning tool that classifies cancers into three distinct subtypes—Immune exclusive (IE), immune suppressive (IS), and immune activated (IA)—which exhibit significant heterogeneity and necessitate customized therapeutic strategies.
Dongqiang Zeng, Yunfang Yu, Wenjun Qiu, Qiyun Ou, Qianqian Mao, Luyang Jiang, Jianhua Wu, Jiani Wu, Huiyan Luo, Peng Luo, Wenchao Gu, Na Huang, Siting Zheng, Shaowei Li, Yonghong Lai, Xiatong Huang, Yiran Fang, Qiongzhi Zhao, Rui Zhou, Huiying Sun, Wei Zhang, Jianping Bin, Yulin Liao, Masami Yamamoto, Tetsuya Tsukamoto, Sachiyo Nomura, Min Shi, Wangjun Liao   +27 more
wiley   +1 more source

High-throughput screening for optimizing adoptive T cell therapies

Experimental Hematology & Oncology
Adoptive T cell therapy is a pivotal strategy in cancer immunotherapy, demonstrating potent clinical efficacy. However, its limited durability often results in primary resistance. High-throughput screening technologies, which include both genetic and non-
Yuchen Zhang, Qinglong Xu, Zhifei Gao, Honghao Zhang, Xiaoling Xie, Meifang Li   +5 more
doaj   +1 more source

DiffMC‐Gen: A Dual Denoising Diffusion Model for Multi‐Conditional Molecular Generation

Advanced Science, EarlyView.
DiffMC‐Gen, a dual‐diffusion model for 2D and 3D molecular generation, simultaneously optimizes multiple key objectives across the drug design process, enabling the generation of novel, target‐specific small‐molecule ligands with high therapeutic potential.
Yuwei Yang, Shukai Gu, Bo Liu, Xiaoqing Gong, Ruiqiang Lu, Jiayue Qiu, Xiaojun Yao, Huanxiang Liu   +7 more
wiley   +1 more source

Explainable AI for computational pathology identifies model limitations and tissue biomarkers [PDF]

arXiv
Introduction: Deep learning models hold great promise for digital pathology, but their opaque decision-making processes undermine trust and hinder clinical adoption. Explainable AI methods are essential to enhance model transparency and reliability. Methods: We developed HIPPO, an explainable AI framework that systematically modifies tissue regions in ...
arxiv  

Approximate Analytical Solution of a Cancer Immunotherapy Model by the Application of Differential Transform and Adomian Decomposition Methods [PDF]

arXiv, 2018
Immunotherapy plays a major role in tumour treatment, in comparison with other methods of dealing with cancer. The Kirschner-Panetta (KP) model of cancer immunotherapy describes the interaction between tumour cells, effector cells and interleukin-2 which are clinically utilized as medical treatment.
arxiv  

KK2DP7 Stimulates CD11b+ Cell Populations in the Spleen to Elicit Trained Immunity for Anti‐Tumor Therapy

Advanced Science, EarlyView.
This study introduces KK2DP7, a dendrimer‐structured peptide adjuvant, as a tool to decode trained immunity's role in antitumor therapy. Splenic CD11b+ cells mediate tumor suppression via TLR2‐IRF7 activation and epigenetic reprogramming, validated by adoptive transfer experiments.
Rui Zhang, Lin Tang, Yusi Wang, Xuejing Zhou, Zhenyu Ding, Li Yang   +5 more
wiley   +1 more source